Skip to main content

Main menu

  • Home
  • Current issue
  • ERJ Early View
  • Past issues
  • ERS Guidelines
  • Authors/reviewers
    • Instructions for authors
    • Submit a manuscript
    • Open access
    • COVID-19 submission information
    • Peer reviewer login
  • Alerts
  • Subscriptions
  • ERS Publications
    • European Respiratory Journal
    • ERJ Open Research
    • European Respiratory Review
    • Breathe
    • ERS Books
    • ERS publications home

User menu

  • Log in
  • Subscribe
  • Contact Us
  • My Cart
  • Log out

Search

  • Advanced search
  • ERS Publications
    • European Respiratory Journal
    • ERJ Open Research
    • European Respiratory Review
    • Breathe
    • ERS Books
    • ERS publications home

Login

European Respiratory Society

Advanced Search

  • Home
  • Current issue
  • ERJ Early View
  • Past issues
  • ERS Guidelines
  • Authors/reviewers
    • Instructions for authors
    • Submit a manuscript
    • Open access
    • COVID-19 submission information
    • Peer reviewer login
  • Alerts
  • Subscriptions

Effect of antifibrotics on short-term outcome after bilateral lung transplantation: a multicentre analysis

Christopher Lambers, Panja M. Boehm, Silvia Lee, Fabio Ius, Peter Jaksch, Walter Klepetko, Igor Tudorache, Robin Ristl, Tobias Welte, Jens Gottlieb
European Respiratory Journal 2018 51: 1800503; DOI: 10.1183/13993003.00503-2018
Christopher Lambers
1Division of Thoracic Surgery, Dept of Surgery, Medical University of Vienna, Vienna, Austria
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Panja M. Boehm
1Division of Thoracic Surgery, Dept of Surgery, Medical University of Vienna, Vienna, Austria
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • ORCID record for Panja M. Boehm
Silvia Lee
2Division of Respiratory Medicine, Dept of Internal Medicine II, Medical University of Vienna, Vienna, Austria
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Fabio Ius
3Hannover Medical School, Dept of Cardiothoracic, Transplant and Vascular Surgery, Hannover, Germany
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Peter Jaksch
1Division of Thoracic Surgery, Dept of Surgery, Medical University of Vienna, Vienna, Austria
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Walter Klepetko
1Division of Thoracic Surgery, Dept of Surgery, Medical University of Vienna, Vienna, Austria
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Igor Tudorache
3Hannover Medical School, Dept of Cardiothoracic, Transplant and Vascular Surgery, Hannover, Germany
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Robin Ristl
4Section for Medical Statistics, Center for Medical Statistics, Informatics and Intelligent Systems, Medical University of Vienna, Vienna, Austria
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Tobias Welte
5Clinic for Pneumology, Hannover Medical School, Hannover, Germany
6Biomedical Research in End-Stage and Obstructive Lung Disease, German Centre for Lung Research (DZL), Hannover, Germany
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Jens Gottlieb
5Clinic for Pneumology, Hannover Medical School, Hannover, Germany
6Biomedical Research in End-Stage and Obstructive Lung Disease, German Centre for Lung Research (DZL), Hannover, Germany
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • Article
  • Figures & Data
  • Info & Metrics
  • PDF
Loading

Abstract

New antifibrotic therapies do not impair the clinical course or survival of patients with interstitial lung disease who underwent bilateral lung transplantation http://ow.ly/7KoG30jyJmQ

To the Editor:

Interstitial lung diseases (ILDs) are a heterogeneous entity of diffuse parenchymal lung diseases characterised by damage of the parenchyma as a result of varying patterns of inflammation and fibrosis [1]. Idiopathic pulmonary fibrosis (IPF) is a specific subgroup of ILDs and has a devastating prognosis [2] with a median survival time of 2–3 years [2–4]. Pirfenidone (Esbriet) and nintedanib (Ofev) were approved for IPF treatment, showing a stabilisation of the disease [5, 6], and are the treatments recommended by international guidelines [1]. Nintedanib was shown to increase the risk of bleeding events in IPF patients during therapy [7] and the European Medicines Agency recommended discontinuation of nintedanib before major surgery but without a definite time frame for discontinuation [8]. Corticosteroids have been the conventional strategy used as treatment in different ILD subtypes despite limited evidence regarding their efficacy [9, 10]. After failure of medical therapy in severe ILD, lung transplantation (LuTx) represents an established therapeutic option in order to improve quality of life and survival [11].

A retrospective analysis after bilateral lung transplantation (BLTx) of patients with ILDs (disease category D in Eurotransplant) was performed in two large European lung transplant centres. Patients with a primary Lung Allocation System (LAS) diagnosis in category D (ILD), including IPF, hypersensitivity pneumonitis, and pulmonary fibrosis, were included. Other lung diseases from LAS diagnosis category D, such as lymphoid interstitial pneumonia, diffuse alveolar damage and acute interstitial pneumonitis, were excluded. The study population comprised all patients who were treated with BLTx between January 2014 and February 2017. Patients receiving unilateral LuTx for ILD were not included (n=7 within the study period). IPF was diagnosed based on the American Thoracic Society (ATS) guidelines [1]. Patients under medical treatment (steroids, nintedanib or pirfenidone) within 4 weeks before transplant surgery were compared to those without medical treatment. Combination therapy of steroids with another antifibrotic agent was sorted into either the pirfenidone or the nintedanib group, respectively. Duration of mechanical ventilation was measured in days until decannulation, extubation or death, whichever occurred first. All complications within the first 4 weeks after surgery or until hospital discharge were recorded. The study was approved by the Ethics Committee of the Medical University of Vienna, Vienna, Austria (EK 1055/2017).

A total of 767 patient records for BLTx patients were screened (Vienna, n=357; Hannover (Germany), n=410) and 132 patients with ILD were identified. 100 (76%) patients were diagnosed as IPF according to the ATS guidelines [2]. Further patient demographics are listed in table 1.

View this table:
  • View inline
  • View popup
TABLE 1

Patient demographics and peri/post-operative patient variables

Of these 132 patients, 108 received a medical regimen containing glucocorticoids (n=72; n=46 patients with IPF), pirfenidone (n=23) or nintedanib (n=13) within 4 weeks before transplantation at the recommended doses. 24 patients had no treatment with steroids, nintedanib or pirfenidone, or therapy was discontinued ≥4 weeks prior to transplantation. Nine (39%) patients with pirfenidone and four (31%) patients with nintedanib therapy received additional steroids.

Outcome parameters are summarised in table 1. The mean surgical intervention time for the BLTx procedure was equally distributed for the specific groups. Despite an overall decrease in mean±sd haemoglobin from 14.2±1.8 to 11.2±1.3 g·dL−1 at day 1 after surgery, no differences in the use of supplemental erythrocyte concentrates during surgery were observed among the groups. Use of extracorporeal membrane oxygenation was similarly distributed for all antifibrotic treatment groups, with a larger proportion in the control group.

Post-operative complications were equally distributed as well. Haemothorax leading to surgical revision occurred in 11 out of 132 patients, with no difference between groups. Wound infections with a need for vacuum-assisted closure were recorded in 12 (9%) patients, with the highest incidence for those on steroid therapy (58%, n=7) and pirfenidone treatment (13%, n=3). The nintedanib group showed no occurrence of severe wound infections at all (n=0). No difference was observed for gastrointestinal bleeding (p=0.52) or renal failure (p=0.815). Patient characteristics and peri/post-operative variables are presented in table 1.

One patient in the steroid group died intraoperatively in hospital and was counted as event-free in the above analysis regarding this end-point. Another patient, also in the steroid group, died at day 16 post-surgery after having experienced surgical revision due to haemothorax. All further patients survived hospitalisation (maximum 64 days) after surgery with no difference between the groups. Median follow up was 21 months (interquartile range 13–29 months), with a maximum of 44 months observation time.

The overall survival between the four groups showed no significant differences (log-rank test p=0.32). The Kaplan–Meier estimate of the 1-year survival probability was 96% (95% CI 80–99.8%) under pirfenidone, 100% (95% CI 65–100%) under nintedanib, 90% (95% CI 81–96%) under steroids and 100% (95% CI 86–100%) without IPF treatment. A total of nine (7%) patients died after BLTx, of whom four patients died during the first 3 months after transplantation (intraoperatively, n=1; severe sepsis, n=3). Four consecutive patients died thereafter within the first year after transplantation (severe sepsis, n=2; non-small cell lung cancer in the donor lung, n=1; bronchial stenosis, n=1) and a single patient in the pirfenidone group died in a car accident after the first year post-BLTx.

IPF is the leading indication for lung transplantation but has an increased mortality on the waiting list compared to other BLTx indications. BLTx has been proven to have improved outcome [12, 13] and is the preferred technique for ILD patients in both study centres. In this large multicentre study, the use of nintedanib and pirfenidone alone or in addition to corticosteroids in BLTx patients was safe, even when administered within the last 4 weeks before surgery. Compared to two previously published studies that confirmed this safety profile in a small sample size [14, 15], our study included a total of 264 anastomoses in the analysis in contrast to a total of 96 anastomoses reported by Leuschner et al. [14]. More importantly, the 1-year survival for patients under pirfenidone therapy was 77% (compared to 96% in our study), 100% for nintedanib (versus 100%) and 91% for the control group (versus 100%). 2-year survival was 77% for pirfenidone (versus 89% in our study) and 82% (versus 100%) in the control group, while nintedanib was excluded from the 2-year analysis [14]. In the study by Delanote et al. [15], a case series of nine patients under antifibrotic treatment, the 1-year survival was 100%, and 80% after 2 years. These results might, in part, be explained by the small number of BLTx performed in both studies (n=34 [14] and n=0 [15]), underlining that these studies are not comparable to our large multicentre study with a total of 132 bilateral lung transplantations.

In conclusion, our study represents the largest cohort of patients with antifibrotic therapy undergoing BLTx for ILD. The data show that BLTx is safe and a valuable therapeutic strategy in end-stage ILD. Our data analysis did not find any impairment of the post-operative course after BLTx associated with pre-transplantation treatment with pirfenidone or nintedanib. Antifibrotic drugs and steroids did not increase the risk for bleeding complications, disturb wound healing or impair the survival.

Footnotes

  • Conflict of interest: C. Lambers has attended advisory board meetings for Boehringer Ingelheim and Roche, outside the submitted work.

  • Conflict of interest: T. Welte has received grants to his institution from Boehringer and Roche during the conduct of the study, lecture and advisory board fees from Boehringer, and has participated in an advisory board on anti-infectives for Roche, outside the submitted work.

  • Conflict of interest: J. Gottlieb has received fees for board membership from Gilead, MSD, Biotest and Therakos, for consultancy from Chiesi, IEK Consulting, Gilead and Breath Therapeutics, and for expert testimony from GLG Research, Navigant and KeyQuest; has received grants or has grants pending from Alnylam and Gilead; and has received payment for lectures from Gilead, Boehringer, Novartis, Basilea, Berlin Chemie and Astellas, and for travel, accommodation or meeting expenses from Biotest.

  • Received December 22, 2017.
  • Accepted March 26, 2018.
  • Copyright ©ERS 2018

References

  1. ↵
    American Thoracic Society, European Respiratory Society. American Thoracic Society/European Respiratory Society International Multidisciplinary Consensus Classification of the Idiopathic Interstitial Pneumonias. Am J Respir Crit Care Med 2002; 165: 277–304.
    OpenUrlCrossRefPubMed
  2. ↵
    1. Raghu G,
    2. Collard HR,
    3. Egan JJ, et al.
    An official ATS/ERS/JRS/ALAT statement: idiopathic pulmonary fibrosis: evidence-based guidelines for diagnosis and management. Am J Respir Crit Care Med 2011; 183: 788–824.
    OpenUrlCrossRefPubMedWeb of Science
    1. Ley B,
    2. Collard HR,
    3. King TE Jr.
    . Clinical course and prediction of survival in idiopathic pulmonary fibrosis. Am J Respir Crit Care Med 2011; 183: 431–440.
    OpenUrlCrossRefPubMedWeb of Science
  3. ↵
    1. Rudd RM,
    2. Prescott RJ,
    3. Chalmers JC, et al.
    British Thoracic Society Study on cryptogenic fibrosing alveolitis: response to treatment and survival. Thorax 2007; 62: 62–66.
    OpenUrlAbstract/FREE Full Text
  4. ↵
    1. King TE Jr.
    , Bradford WZ, Castro-Bernardini S, et al. A phase 3 trial of pirfenidone in patients with idiopathic pulmonary fibrosis. N Engl J Med 2014; 370: 2083–2092.
    OpenUrlCrossRefPubMedWeb of Science
  5. ↵
    1. Richeldi L,
    2. du Bois RM,
    3. Raghu G, et al.
    Efficacy and safety of nintedanib in idiopathic pulmonary fibrosis. N Engl J Med 2014; 370: 2071–2082.
    OpenUrlCrossRefPubMedWeb of Science
  6. ↵
    1. Corte T,
    2. Bonella F,
    3. Crestani B, et al.
    Safety, tolerability and appropriate use of nintedanib in idiopathic pulmonary fibrosis. Respir Res 2015; 16: 116.
    OpenUrl
  7. ↵
    European Medicines Agency. Ofev – nintedanib. www.ema.europa.eu/ema/index.jsp?curl=pages/medicines/human/medicines/003821/human_med_001834.jsp&mid=WC0b01ac058001d124 Date last updated: September 19, 2017. Date last accessed: September 23, 2017.
  8. ↵
    1. Hubbard R,
    2. Johnston I,
    3. Britton J
    . Survival in patients with cryptogenic fibrosing alveolitis: a population-based cohort study. Chest 1998; 113: 396–400.
    OpenUrlCrossRefPubMedWeb of Science
  9. ↵
    1. Nagai S,
    2. Kitaichi M,
    3. Hamada K, et al.
    Hospital-based historical cohort study of 234 histologically proven Japanese patients with IPF. Sarcoid Vasc Diffuse Lung Dis 1999; 16: 209–214.
    OpenUrl
  10. ↵
    1. Thabut G,
    2. Mal H,
    3. Castier Y, et al.
    Survival benefit of lung transplantation for patients with idiopathic pulmonary fibrosis. J Thorac Cardiovasc Surg 2003; 126: 469–475.
    OpenUrlCrossRefPubMedWeb of Science
  11. ↵
    1. Christie JD,
    2. Edwards LB,
    3. Aurora P, et al.
    Registry of the International Society for Heart and Lung Transplantation: twenty-fifth official adult lung and heart/lung transplantation report – 2008. J Heart Lung Transplant 2008; 27: 957–969.
    OpenUrlCrossRefPubMedWeb of Science
  12. ↵
    1. Valapour M,
    2. Paulson K,
    3. Smith JM, et al.
    OPTN/SRTR 2011 annual data report: lung. Am J Transplant 2013; 13: Suppl. 1, 149–177.
    OpenUrlCrossRefPubMed
  13. ↵
    1. Leuschner G,
    2. Stocker F,
    3. Veit T, et al.
    Outcome of lung transplantation in idiopathic pulmonary fibrosis with previous anti-fibrotic therapy. J Heart Lung Transplant 2017 in press [https://doi.org/10.1016/j.healun.2017.07.002].
  14. ↵
    1. Delanote I,
    2. Wuyts WA,
    3. Yserbyt J, et al.
    Safety and efficacy of bridging to lung transplantation with antifibrotic drugs in idiopathic pulmonary fibrosis: a case series. BMC Pulm Med 2016; 16: 156.
    OpenUrl
PreviousNext
Back to top
View this article with LENS
Vol 51 Issue 6 Table of Contents
European Respiratory Journal: 51 (6)
  • Table of Contents
  • Index by author
Email

Thank you for your interest in spreading the word on European Respiratory Society .

NOTE: We only request your email address so that the person you are recommending the page to knows that you wanted them to see it, and that it is not junk mail. We do not capture any email address.

Enter multiple addresses on separate lines or separate them with commas.
Effect of antifibrotics on short-term outcome after bilateral lung transplantation: a multicentre analysis
(Your Name) has sent you a message from European Respiratory Society
(Your Name) thought you would like to see the European Respiratory Society web site.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Print
Citation Tools
Effect of antifibrotics on short-term outcome after bilateral lung transplantation: a multicentre analysis
Christopher Lambers, Panja M. Boehm, Silvia Lee, Fabio Ius, Peter Jaksch, Walter Klepetko, Igor Tudorache, Robin Ristl, Tobias Welte, Jens Gottlieb
European Respiratory Journal Jun 2018, 51 (6) 1800503; DOI: 10.1183/13993003.00503-2018

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero

Share
Effect of antifibrotics on short-term outcome after bilateral lung transplantation: a multicentre analysis
Christopher Lambers, Panja M. Boehm, Silvia Lee, Fabio Ius, Peter Jaksch, Walter Klepetko, Igor Tudorache, Robin Ristl, Tobias Welte, Jens Gottlieb
European Respiratory Journal Jun 2018, 51 (6) 1800503; DOI: 10.1183/13993003.00503-2018
Reddit logo Technorati logo Twitter logo Connotea logo Facebook logo Mendeley logo
Full Text (PDF)

Jump To

  • Article
    • Abstract
    • Footnotes
    • References
  • Figures & Data
  • Info & Metrics
  • PDF
  • Tweet Widget
  • Facebook Like
  • Google Plus One

More in this TOC Section

Agora

  • Airway immune responses to COVID-19 vaccination in COPD patients
  • Wider access to rifapentine-based regimens is needed for TB care globally
  • Screening for PVOD in heterozygous EIF2AK4 variant carriers
Show more Agora

Research letters

  • CFTR modulators and platelet activation in blood of COVID-19 patients
  • Implications of new ERS/ATS standards on lung function test interpretation
  • Impact of depression and anxiety on exacerbation risk in bronchiectasis
Show more Research letters

Related Articles

Navigate

  • Home
  • Current issue
  • Archive

About the ERJ

  • Journal information
  • Editorial board
  • Press
  • Permissions and reprints
  • Advertising

The European Respiratory Society

  • Society home
  • myERS
  • Privacy policy
  • Accessibility

ERS publications

  • European Respiratory Journal
  • ERJ Open Research
  • European Respiratory Review
  • Breathe
  • ERS books online
  • ERS Bookshop

Help

  • Feedback

For authors

  • Instructions for authors
  • Publication ethics and malpractice
  • Submit a manuscript

For readers

  • Alerts
  • Subjects
  • Podcasts
  • RSS

Subscriptions

  • Accessing the ERS publications

Contact us

European Respiratory Society
442 Glossop Road
Sheffield S10 2PX
United Kingdom
Tel: +44 114 2672860
Email: journals@ersnet.org

ISSN

Print ISSN:  0903-1936
Online ISSN: 1399-3003

Copyright © 2023 by the European Respiratory Society